about
A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinomaTransgenic CHD1L expression in mouse induces spontaneous tumors.CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients.Overexpression of GPR39 contributes to malignant development of human esophageal squamous cell carcinoma.Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression.Overexpression of cathepsin Z contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinomaOverexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma.Chemically-induced cancers do not originate from bone marrow-derived cellsInterleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expressionRegulatory factors governing adenosine-to-inosine (A-to-I) RNA editing.Overexpression of N-terminal kinase like gene promotes tumorigenicity of hepatocellular carcinoma by regulating cell cycle progression and cell motility.Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma.RNA editome imbalance in hepatocellular carcinoma.Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma.Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.Characterization of CACNA2D3 as a putative tumor suppressor gene in the development and progression of nasopharyngeal carcinoma.Downregulation of the novel tumor suppressor DIRAS1 predicts poor prognosis in esophageal squamous cell carcinoma.SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma.Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma.Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma.Role of translationally controlled tumor protein in cancer progression.Establishment and characterization of human non-small cell lung cancer cell lines.Down-regulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma.AKR7A3 suppresses tumorigenicity and chemoresistance in hepatocellular carcinoma through attenuation of ERK, c-Jun and NF-κB signaling pathways.Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.An RNA editing/dsRNA binding-independent gene regulatory mechanism of ADARs and its clinical implication in cancer.Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-like (CHD1l) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival.Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors.ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer.SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice.Bidirectional regulation of adenosine-to-inosine (A-to-I) RNA editing by DEAH box helicase 9 (DHX9) in cancerADAR1: a promising new biomarker for esophageal squamous cell carcinoma?AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancerCis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer developmentAuthor Correction: Systematic evaluation and optimization of the experimental steps in RNA G-quadruplex structure sequencingCAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung CancerAberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosisSystematic evaluation and optimization of the experimental steps in RNA G-quadruplex structure sequencing
P50
Q28292754-4922F1C2-5849-4F96-9BE4-6E3AD9E6CCE3Q33496125-E342FA6C-A9B5-4176-B188-5343F4482246Q33755370-DE831226-4DAB-4677-8071-C451B135BEAFQ33830089-3D08C234-7C98-4B1C-911C-01E38A5E2C05Q33961542-D94ABAFC-4477-48B9-8F6D-71B760498FC6Q34037880-29ED0D21-574D-4B37-8305-D11422015DEFQ34095605-E9F94294-E6B2-4A0A-BAEB-5B9ADEA5DE7DQ34146135-E798025A-0CAC-4341-9D41-859DDAF551ACQ34438689-DC0AF602-2DEF-4C31-86D9-DCB9D5829723Q34461786-7BEA1A79-72F1-411E-9A55-87A1876C5AAFQ35176391-1154948A-4F50-4E01-B204-19AFB2282217Q37777019-7C7A1283-F34D-4A03-947C-145E752A937AQ38189960-934E4610-6A2A-4987-8723-A6E503068687Q38314621-56FD6C42-1A14-4F9B-8EE8-564B73A5BC77Q38861160-0D7CF1FB-F656-4DD8-80F2-79DBD676BDE2Q39049592-93245DB1-44F8-431F-A524-4F6F658A19CFQ39155509-C9ADC2AB-308D-45DF-9C57-E5F7DAB6B27BQ39189269-7D94EB0E-71D8-475D-A834-107F170AF90DQ39351710-1AA906AD-CED5-409F-9261-9D2335252583Q39409326-702DB708-7B41-4AE8-AEC0-401F86152065Q39630589-0BE40585-A6F0-4194-9C97-69AA75ADDBD0Q42137083-1466A3F1-880C-4B1C-BC0F-FA62E9D0A792Q42817787-9299A182-75CC-4DEE-97EB-11E1F71C160AQ43139836-143504B3-8A82-40F3-99B7-5E4496413910Q44788723-2E295048-B0A8-48A5-AB49-60633AD6A808Q45371340-45A6FCDC-9D3C-4AF4-B581-A0E5A0490978Q47268042-6B863BEC-92B7-4FF1-BF7F-4ECBCC54A261Q47803497-5331A76B-AFD1-41E0-8C07-34A624921D93Q49960728-302BEAF1-A81A-41AE-BA67-2B40F57D4A58Q50518741-E13BE83A-C987-4B44-BDC9-AF93AE984486Q51666682-76C1B0ED-DD39-43B1-9730-A6B7EA2754E8Q53263915-1865EBC5-0B65-494D-BAC4-6D3544997B90Q57753095-0989ED81-0AB1-4EBF-A3DF-E1ED3EA9C1C8Q88078418-D73754A5-D8DC-469C-9227-D7F885F8C59DQ89170106-37D1F98F-78B5-480C-9CDB-2AD9F4902E76Q89601948-90770E2F-1E8D-4355-8F83-741E334B94DAQ89882488-D19CA9FD-392E-4066-B399-8F5E61196EE7Q90169812-206A3092-A38C-4F56-8F1F-9F3511703AAFQ90644460-08AF69F1-4043-43DB-A3D5-BF4104618299Q92419630-E0C9EC56-BDB8-4A30-9319-89E82D8B4BAE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Leilei Chen
@ast
Leilei Chen
@en
Leilei Chen
@es
Leilei Chen
@nl
type
label
Leilei Chen
@ast
Leilei Chen
@en
Leilei Chen
@es
Leilei Chen
@nl
prefLabel
Leilei Chen
@ast
Leilei Chen
@en
Leilei Chen
@es
Leilei Chen
@nl
P106
P108
P1153
23569135400
P31
P496
0000-0002-1987-3878